Circulating Tumor DNA – A Biomarker for Adjuvant Chemotherapy?
Listen to Van Morris, directly from ASCO GI, discuss the NRG-GI005 (COBRA) trial, a phase II study examining the use of circulating tumor DNA as a biomarker for adjuvant chemotherapy benefit in stage IIa colon cancer.